Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

This Phase II trial is testing repotrectinib in elderly or frail patients with advanced non-small cell lung cancer (NSCLC) whose tumors carry a specific genetic change called a ROS1 rearrangement. Repotrectinib is a targeted drug designed to block the abnormal ROS1 protein that drives cancer growth. **You may be eligible if...** - You are 18 or older AND either aged 70+ or have limited daily function (ECOG performance status 2 or higher) - Your lung cancer has been confirmed to have a ROS1 gene rearrangement by a molecular test - You have at least one measurable tumor on imaging - You are in otherwise reasonable health with adequate blood, liver, and kidney function **You may NOT be eligible if...** - You have another active cancer within 2 years - You have active hepatitis B or C, active tuberculosis, or HIV - You have significant heart disease or had a recent heart attack or stroke - You are pregnant or breastfeeding - You are currently in another therapeutic clinical trial Talk to your doctor to see if this trial is right for you.